References

ADME/PK as part of a rational approach to drug discovery

10.1016/s1359-6446(00)01540-3 · 2000 · External reference

Pharmacokinetic/pharmacodynamic studies in drug product development

10.1002/jps.1167 · 2002 · External reference

Applied concepts in PBPK modeling: how to build a PBPK/PD model

10.1002/psp4.12134 · 2016 · External reference

A generic whole body physiologically based pharmacokinetic model for therapeutic proteins in PK-Sim

10.1007/s10928-017-9559-4 · 2018 · External reference

Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework

10.1038/nrd4309 · 2014 · External reference

Systems pharmacology - Towards the modeling of network interactions

10.1016/j.ejps.2016.04.027 · 2016 · External reference

Functional comparison of interferon-α subtypes reveals potent Hepatitis B virus suppression by a concerted action of interferon-α and interferon-γ signaling

10.1002/hep.31282 · 2021 · External reference

Transcriptomics in interferon-α-treated patients identifies inflammation-, neuroplasticity- and oxidative stress-related signatures as predictors and correlates of depression

10.1038/npp.2016.50 · 2016 · External reference

Quantitative systems pharmacology of interferon alpha administration: A multi-scale approach

10.1371/journal.pone.0209587 · 2019 · External reference

Combining theoretical analysis and experimental data generation reveals IRF9 as a crucial factor for accelerating interferon α-induced early antiviral signalling

10.1111/j.1742-4658.2010.07880.x · 2010 · External reference

Temporal and spatial resolution of type I and III interferon responses in vivo

10.1128/jvi.00303-10 · 2010 · External reference

Expansion of functional personalized cells with specific transgene combinations

10.1038/s41467-018-03408-4 · 2018 · External reference

Preparation of isolated rat liver cells

10.1016/s0091-679x(08)61797-5 · 1976 · External reference

COPASI--a complex pathway simulator

10.1093/bioinformatics/btl485 · 2006 · External reference

Mathematical modeling of intracellular signaling pathways

10.1186/1471-2202-7-s1-s10 · 2006 · External reference

10.1007/b97636

10.1007/b97636 · 2004 · External reference

Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A/D(Bgl), and I interferons and mouse alpha-interferon in mice

10.1089/jir.1986.6.207 · 1986 · External reference

The kinetics of interferon clearance in mice: comparison of mouse and human interferon

1984 · External reference

Study of the in vivo priming effect of interferon in mice

10.1099/0022-1317-67-12-2731 · 1986 · External reference

Antiviral actions of interferons

10.1128/cmr.14.4.778-809.2001 · 2001 · External reference

Mx proteins: antiviral gatekeepers that restrain the uninvited

10.1128/mmbr.00024-13 · 2013 · External reference

Interferon-inducible antiviral effectors

10.1038/nri2314 · 2008 · External reference

Mouse Mx2 gene: organization, mRNA expression and the role of the interferon-response promoter in its regulation

10.1016/s0378-1119(03)00428-1 · 2003 · External reference

Ensemble modeling for analysis of cell signaling dynamics

10.1038/nbt1330 · 2007 · External reference

Development of a physiologically based computational kidney model to describe the renal excretion of hydrophilic agents in rats

10.3389/fphys.2012.00494 · 2013 · External reference

Extrapolating from animals to humans

2012 · External reference

Issues in collecting, processing and storing human tissues and associated information to support biomedical research

10.3233/cbm-2011-0183 · 2010 · External reference

Genomic responses in mouse models poorly mimic human inflammatory diseases

10.1073/pnas.1222878110 · 2013 · External reference

Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation

10.1111/imr.12001 · 2012 · External reference

Type I interferon receptor is a primary regulator of target-mediated drug disposition of interferon-beta in mice

10.1124/jpet.110.167650 · 2010 · External reference

Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the alpha and betaL subunits of the type I interferon receptor

1996 · External reference

Of mice and not men: differences between mouse and human immunology

10.4049/jimmunol.172.5.2731 · 2004 · External reference

Viral infections in humans and mice with genetic deficiencies of the type I IFN response pathway

10.1002/eji.202048793 · 2021 · External reference

Hepatic gene expression discriminates responders and nonresponders in treatment of chronic hepatitis C viral infection

10.1053/j.gastro.2005.01.059 · 2005 · External reference

Poor response to interferon treatment for chronic hepatitis C in human immunodeficiency virus-infected haemophiliacs

10.1046/j.1365-2516.2000.00444.x · 2000 · External reference

Identifying responders and nonresponders to interferon therapy in multiple sclerosis

2014 · External reference

Why is there a poor response to combined therapy with interferon alfa 2b and ribavirin in patients with chronic hepatitis C?

2002 · External reference

Type I interferons in infectious disease

10.1038/nri3787 · 2015 · External reference

Interferons α and β in cancer: therapeutic opportunities from new insights

10.1038/s41573-018-0011-2 · 2019 · External reference

Cytokines in clinical cancer immunotherapy

10.1038/s41416-018-0328-y · 2019 · External reference

Quantitative systems pharmacology approaches for immuno-oncology: adding virtual patients to the development paradigm

10.1002/cpt.1987 · 2021 · External reference